Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BC Cancer Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study H15-02103
Men suitable for prostate brachytherapy as monotherapy will undergo multiparametric Magnetic Resonance Imaging for staging and identification of a dominant lesion and will be randomly selected for either a single low dose rate permanent seed implant or 2 fractions of high dose rate brachytherapy. Using image registration techniques, dominant lesions will be biopsied under anesthesia at the start of the brachytherapy procedure. Biopsies will reviewed for tumor Gleason score and sent for Cell Cycle Progression testing (Prolaris). Patients receiving high dose rate brachytherapy will also have biopsies between the 2 fractions to assess tumor changes induced from the first fraction. Post implant quality assurance will determine the dose to the dominant lesions and compare these between the 2 types of brachytherapy. Post implant symptoms will be tracked for severity and time course.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low dose rate brachytherapy | Active Comparator | Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality. |
|
| High dose rate brachytherapy | Experimental | Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required. HDR brachytherapy is also accomplished as an out-patient. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low dose rate prostate brachytherapy | Radiation | Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance |
|
| Measure | Description | Time Frame |
|---|---|---|
| The difference in Quality of Life in the urinary domain between LDR and HDR brachytherapy. | The urinary domain of the EPIC prostate cancer specific QOL questionnaire will be assessed. | 0-60 months |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life in the bowel and sexual domains | The EPIC score in the bowel and sexual domains will be evaluated at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months | 0-60 months |
| Time to return to baseline +/- 3 points for the International Prostate Symptom Score |
Not provided
Inclusion Criteria:
Favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
Clinical stage T1c-T2b, PSA < 20, Gleason < 8
ECOG 0-1
Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor
Extensive favorable-risk disease is defined as:
Selected intermediate risk patients not defined above
No androgen deprivation therapy (ADT)
Prostate volume by TRUS ≤ 60 cc.
Not eligible for, or accepting of, active surveillance according to NCCN guidelines.
Signed study specific informed consent.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ross Halperin, MD | British Columbia Cancer Agency Program Director | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| British Columbia Cancer Agency Center for the Southern Interior | Kelowna | British Columbia | V1Y5L3 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24958556 | Background | Crook J, Ots A, Gaztanaga M, Schmid M, Araujo C, Hilts M, Batchelar D, Parker B, Bachand F, Milette MP. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. Brachytherapy. 2014 Sep-Oct;13(5):433-41. doi: 10.1016/j.brachy.2014.05.006. Epub 2014 Jun 20. | |
| 24080299 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 7, 2017 | Jan 29, 2018 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| High dose rate prostate brachytherapy | Radiation | Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate |
|
|
The IPS Score will be assessed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months |
| 0-60 months |
| Acute and long term toxicity | Acute and long-term toxicity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE V4) at each follow up time point | [Time Frame: 0-10 years] |
| Biochemical Outcome | PSA will be recorded every 6 months to 5 years and then annually to 10 years | 5-10 years |
| Histologic Outcome | Prostate re-biopsy will be performed at 36 months to assess the local efficacy of treatment | 3 years |
| Cell cycle progression score | For those patients consenting to targeted biopsies under anesthesia at the start of their brachytherapy procedure (separate optional consent) MRI-TRUS fusion accuracy will be verified by targeted biopsies and Biopsy material will be sent for genetic testing to determine Cell cycle Progression scores for both arms of the trial to ultimately correlate with outcome. | 1 month to 10 years |
| Tumor oxygenation and cell cycle distribution | For patients receiving 2 fractions of high dose rate brachytherapy, biopsy between the 2 fractions will assess radiosensitivity by evaluating changes in oxygenation and cell cycle distribution between the 2 fractions, for ultimate correlation with efficacy | 1 month to 10 years. |
| Batchelar D, Gaztanaga M, Schmid M, Araujo C, Bachand F, Crook J. Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning. Brachytherapy. 2014 Jan-Feb;13(1):75-9. doi: 10.1016/j.brachy.2013.08.004. Epub 2013 Sep 27. |
| 22513104 | Background | Schmid M, Crook JM, Batchelar D, Araujo C, Petrik D, Kim D, Halperin R. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. Brachytherapy. 2013 Jan-Feb;12(1):56-64. doi: 10.1016/j.brachy.2012.03.002. Epub 2012 Apr 17. |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |